We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Akebia Announces Initiation of Phase 2a Dose Range Finding Study of AKB-6548 for Anemia

News   Jun 27, 2011

 
Akebia Announces Initiation of Phase 2a Dose Range Finding Study of AKB-6548 for Anemia
 
 
 

RELATED ARTICLES

Stage Set for Uncovering Multiple Autoimmune Drug Targets

News

The identification of molecular signatures that reflect the pathology of lupus and arthritis provide new insights into tissue damage, and set the stage for uncovering potential drug target candidates.

READ MORE

Powerful Antibody Inhibits Multiple Strains of Norovirus

News

An antibody has been identified that broadly inhibits multiple strains of pandemic norovirus, a major step forward in the development of an effective vaccine for the dreaded stomach virus.

READ MORE

Cancer-killing Virus Gives Immunotherapy a Helping Hand Tackling Hard-to-treat Cancer

News

Combining a cancer-killing virus with immunotherapy could effectively treat advanced cancers that affect the limbs, a new study reveals.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE